Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00296270
Other study ID # RIR13914
Secondary ID
Status Completed
Phase N/A
First received February 23, 2006
Last updated February 23, 2006
Start date March 2005
Est. completion date June 2005

Study information

Verified date February 2006
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority Canada: Institutional Review BoardUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

Objectives: To determine whether people systematically misremember the “myths” (false information) as true, and to assess effects on perceptions of risk and behavioral intentions.


Description:

Public information campaigns often warn people about false and unreliable medical claims by juxtaposing “myths” and “facts.” The effectiveness of such communications has rarely been assessed. We assessed whether people systematically misremember the “myths” (false information) as true, and to assess effects on perceptions of risk and behavioral intentions.

In an experimental study, participants read either a published CDC flyer on “Facts and Myths” about the flu vaccine, or a “Facts Only” version; a separate control group read no flyer. Participants completed the outcome measures either immediately or after 30 minutes.

Primary measures were memory for information about the flu presented in the flyer, ratings of perceived risks associated with the flu, and personal intentions to get vaccinated in the upcoming season.

After a delay of 30 minutes, participants who read the “Facts and Myths” flyer systematically misremembered myths as facts. Both versions of the flyer had the immediate effect of increasing intentions to get a flu vaccine, compared to the control group. After 30 minutes, however, participants who read the “Facts and Myths” flyer reported lower intentions to get vaccinated, compared to those who read the same flyer with no delay, and compared to all participants who read the “Facts Only” flyer.

In sum, people show a bias to think that incompletely remembered information is true, turning “myths” into “facts.” Hence public information campaigns should emphasize information that is true. Repeating false information, even as a warning, can create the unintended consequence of belief in the information.


Recruitment information / eligibility

Status Completed
Enrollment 175
Est. completion date June 2005
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 26 Years
Eligibility Inclusion Criteria:

- Must be able to read and write fluent English

Exclusion Criteria:

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Educational/Counseling/Training


Related Conditions & MeSH terms


Intervention

Behavioral:
Memory for truth


Locations

Country Name City State
Canada Rotman School of Management, University of Toronto Toronto Ontario
United States University of Michigan Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Memory for truth of information in a flyer.
Secondary Intention to get flu vaccine in upcoming season.
See also
  Status Clinical Trial Phase
Completed NCT03246100 - Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates_2nd Trial in Colorado N/A
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT02761551 - Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates N/A
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Completed NCT03735147 - Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children Phase 4
Completed NCT02831608 - Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis Phase 4
Completed NCT02560909 - Adjuvanted Influenza Vaccine in Stem Cell Transplant Phase 4
Withdrawn NCT01623232 - MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly Phase 1/Phase 2
Completed NCT00961337 - Evaluation of a School-based Influenza Vaccination Program Phase 4
Completed NCT00402805 - Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy Phase 4
Completed NCT00222638 - Influenza Vaccination and Oral Anticoagulant Therapy Phase 4
Active, not recruiting NCT03734237 - A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD Phase 4
Completed NCT01013675 - Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly Phase 2
Completed NCT00306995 - Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population Phase 2
Completed NCT01310413 - Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age Phase 3
Completed NCT00449670 - Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults Phase 3
Completed NCT01788228 - Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure Phase 3
Recruiting NCT05521763 - Influenza Vaccine Uptake Among Healthcare Workers N/A
Completed NCT00718120 - Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years Phase 3
Completed NCT00430521 - Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A) Phase 2